{{Rsnum
|rsid=699946
|Chromosome=6
|position=43764932
|Orientation=plus
|GMAF=0.2576
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 67.3 | 32.7 | 0.0
| HCB | 24.8 | 57.7 | 17.5
| JPT | 38.9 | 46.9 | 14.2
| YRI | 72.8 | 25.9 | 1.4
| ASW | 70.2 | 24.6 | 5.3
| CHB | 24.8 | 57.7 | 17.5
| CHD | 27.5 | 56.0 | 16.5
| GIH | 63.4 | 31.7 | 5.0
| LWK | 62.0 | 31.5 | 6.5
| MEX | 56.9 | 36.2 | 6.9
| MKK | 35.9 | 48.7 | 15.4
| TSI | 69.6 | 26.5 | 3.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=19553626
|Title=Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy
}}

{{PMID Auto
|PMID=22258388
|Title=Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes
}}

{{PMID Auto
|PMID=19308252
|Title=Genetic variation in VEGF does not contribute significantly to the risk of congenital cardiovascular malformation.
|OA=1
}}

{{PMID Auto
|PMID=21744122
|Title=VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration.
}}

{{PMID Auto
|PMID=24652518
|Title=VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT)
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}